The rationale for treating patients with early-stage HR-positive breast cancer with abemaciclib and endocrine therapy.
Kevin Kalinsky, MD, MS: We’ve known from metastatic disease that with CDK4/6 inhibitors there can be significant advantage of utilizing them in the metastatic setting.
And we’ve seen across the various studies in the metastatic setting progression-free survival benefit and for some of the agents an overall survival benefit. So there’s been a lot of interest about utilizing these agents in the early-stage setting.
And the data that we’ve seen with palbociclib [Ibrance] did not yield an improvement in invasive disease-free survival. But with monarchE we did see an improvement with invasive disease-free survival.
And how that study was designed, is that these were some higher risk patients and all those patients received endocrine therapy plus or minus 2 years of abemaciclib [Verzenio]. And these data have been updated, and recently published in the Annals of Oncology, demonstrating that those 2 years lead to an improvement in invasive disease-free survival.
The drug was approved based upon these data, meaning abemaciclib was approved in the early-stage setting in patients who are high risk, and by that I mean that they had a Ki67 that was 20% or greater and had 1 to 3 nodes involved. And had other high-risk features like grade 3 tumors or tumors that are greater than 5 centimeters. And the FDA [Food and Drug Administration] approved this particular agent in that setting and that’s what’s included in the label.
ASCO [American Society of Clinical Oncology] since has come out and been a little bit more open in terms of definition of high risk. But for this particular patient, she does meet these criteria of grade 2 tumor, 1 to 3 nodes involved, high Ki67. It would be totally appropriate to think about abemaciclib for this patient.
When doing an analysis looking at Ki67, what was seen, if you look in those different cohorts that had a lower Ki67 or a higher Ki67, the absolute benefit was different between the population.
So the population who had a higher Ki67 had a numeric benefit of invasive disease-free survival after about 3 years or so, of about 7%. And that was lower in the population who had a lower Ki67.
Though the hazard ratio is the same between those 2 populations, the FDA approved the drug in those patients who have a higher Ki67 because those patients have a higher risk.
And that lead towards that population having a higher numeric benefit in terms of the absolute benefit with the abemaciclib.
Transcript edited for clarity.
Case: A 67-Year-Old Woman with ER+/PR+ Breast Cancer
Initial Presentation
Clinical work-up
Treatment
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen